Surveillance après un traitement du cancer du sein

Breast cancer screening and therapeutic advances have significantly decreased breast cancer mortality. Nearly 80% of patients with a localized disease will experience a prolonged survival and the organization of their monitoring is critical to early detection of local or metastatic relapse. Annual mammography is recommanded for the follow up and no further imaging examination is routinely necessary. Early diagnosis of metastatic relapse has not demonstrated evidence of survival benefit. However, treatments are not without toxicities and data about long-term complications are missing. The socio-economic consequences for these patients need to be evaluated and cardiovascular toxicities of chemotherapy and hormonal therapy are probably underestimated.